Bernice Welles - Spectrum Pharmaceuticals Independent Director
| SPPIDelisted Stock | USD 1.03 0.00 0.00% |
Director
Dr. Bernice R. Welles is an Independent Director of the company since June 2018. Dr. Welles is a Partner and Managing Director with IPF Management S.A. which manages funds that provide growth capital to life science companies. Dr. Welles served as Chief Executive Officer at Alquest Therapeutics, Inc., a neurodegenerative drug development company, from June 2010 to 2013, and Chief Medical Officer at Enject, Inc., a medical device company, from 2009 to 2013. Prior to that she was Vice President, Development at DiObex, Inc., a venturebacked biotechnology company. Dr. Welles has VC experience having been Venture Partner at MPM Capital, L.P. for two years and extensive pharmaceutical experience having been Vice President, Product Development and Senior Director and Director, Specialty Therapeutics Unit, Medical Affairs and Clinical Scientist, Medical Affairs at Genentech, Inc. for eight years. since 2018.
| Age | 65 |
| Tenure | 6 years |
| Phone | 617 586 3900 |
| Web | https://www.sppirx.com |
Spectrum Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3821) % which means that it has lost $0.3821 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6502) %, meaning that it created substantial loss on money invested by shareholders. Spectrum Pharmaceuticals' management efficiency ratios could be used to measure how well Spectrum Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 29.43 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Spectrum Pharmaceuticals has a current ratio of 1.75, which is within standard range for the sector. Debt can assist Spectrum Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Spectrum Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Spectrum Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Spectrum to invest in growth at high rates of return. When we think about Spectrum Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Gregory Behar | Seres Therapeutics | 48 | |
| Christopher Paige | AVROBIO | 64 | |
| Scott Morrison | Corvus Pharmaceuticals | 60 | |
| MD FACP | Hepion Pharmaceuticals | N/A | |
| Kendra Adams | Agios Pharm | N/A | |
| Frank Palantoni | Lexicon Pharmaceuticals | 60 | |
| Kenneth Weg | Karyopharm Therapeutics | 77 | |
| Walter Moos | Rigel Pharmaceuticals | 63 | |
| Peter Hutt | Seres Therapeutics | 80 | |
| Kaye FosterCheek | Agios Pharm | 58 | |
| Annalisa Jenkins | AVROBIO | 51 | |
| John Maraganore | Bluebird bio | 54 | |
| John Brancaccio | Hepion Pharmaceuticals | 69 | |
| Avraham Molcho | BioLineRx | 59 | |
| Douglas Melton | Bluebird bio | 64 | |
| Timothy Block | Hepion Pharmaceuticals | 61 | |
| Peter Thompson | Corvus Pharmaceuticals | 56 | |
| Bradford Goodwin | Rigel Pharmaceuticals | 63 | |
| Werner Cautreels | Seres Therapeutics | N/A | |
| Karin Eastham | Geron | 67 | |
| Gina Consylman | Verastem | 45 | |
Management Performance
| Return On Equity | -1.65 | |||
| Return On Asset | -0.38 |
Spectrum Pharmaceuticals Leadership Team
Elected by the shareholders, the Spectrum Pharmaceuticals' board of directors comprises two types of representatives: Spectrum Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spectrum. The board's role is to monitor Spectrum Pharmaceuticals' management team and ensure that shareholders' interests are well served. Spectrum Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spectrum Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stuart Krassner, Independent Director | ||
| Raymond Cohen, Independent Director | ||
| Michael Grabow, Exec Officer | ||
| Nora Brennan, Ex Officer | ||
| Joseph Turgeon, Pres and COO | ||
| Dolatrai Vyas, Independent Director | ||
| Keith McGahan, Senior Vice President Chief Legal Officer and Corporate Secretary | ||
| LLM JD, Chief VP | ||
| MD MBA, VP Devel | ||
| Jeffrey Vacirca, Director | ||
| William Ashton, Independent Director | ||
| Luigi Lenaz, Director | ||
| Gilles Gagnon, Director | ||
| Bimal Shah, VP Devel | ||
| Kurt Gustafson, CFO, Principal Accounting Officer and Executive VP | ||
| Rajesh Shrotriya, Chairman of the Board, CEO | ||
| Elizabeth Czerepak, Director | ||
| Bernice Welles, Independent Director | ||
| Thomas Riga, CEO Pres | ||
| Anthony Maida, Independent Director | ||
| MD FRCPC, Ex Officer |
Spectrum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spectrum Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.65 | |||
| Return On Asset | -0.38 | |||
| Profit Margin | (2.52) % | |||
| Operating Margin | (2.47) % | |||
| Current Valuation | 185.27 M | |||
| Shares Outstanding | 205.25 M | |||
| Shares Owned By Insiders | 11.00 % | |||
| Shares Owned By Institutions | 22.93 % | |||
| Number Of Shares Shorted | 3.33 M | |||
| Price To Earning | (19.44) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Spectrum Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Spectrum Pharmaceuticals' short interest history, or implied volatility extrapolated from Spectrum Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Spectrum Stock
If you are still planning to invest in Spectrum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spectrum Pharmaceuticals' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |